News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Funding moves take on hepatitis B

Funding moves take on hepatitis B

New moves to tackle the leading cause of liver cancer have been announced by drug-funding agency PHARMAC.

From 1 May 2006 access will be widened to lamivudine (Zeffix), and a new type of hepatitis therapy, adefovir (Hepsera) will be funded.

Hepatitis B, a virus that causes infection of the liver, causes up to 90 percent of liver cancer. Hepatitis B is the most prevalent form of hepatitis, estimated to affect about 80,000 New Zealanders, most of whom will never know they carry the virus until they present with symptoms from advanced liver disease.

New Zealand has high rates of Hepatitis B compared to other countries, with higher rates of infection among Maori, Pacific Island ,Chinese and South East Asian communities.

PHARMAC Chief Executive Wayne McNee says the changes to lamivudine (Zeffix) access criteria and the listing of adefovir (Hepsera) will mean further treatment options for about 1000 patients over three years. These decisions are expected to result in additional expenditure of $6.3 million over five years.

“This is the most prevalent form of hepatitis and left untreated can lead to complications such as liver failure, which requires liver transplantation, or liver cancer. In some cases, it can be fatal.” Wayne McNee says.

“Antiviral therapies such as lamivudine and adefovir are important in preventing the disease advancing to the stage where patients develop other complications. This is a decision based on clinical advice that there are further benefits in extending access to lamivudine, and listing a new treatment option for Hepatitis B, adefovir.”

“Adefovir is a relatively new treatment for hepatitis, having only been approved by Medsafe in August 2005. We are pleased to have been able to move quickly to subsidise this important medicine for patients.”

Associate Professor Ed Gane, Hepatologist in Charge of the NZ Liver Unit at Auckland City Hospital, welcomes the changes.

“Chronic hepatitis B affects more than 80,000 New Zealanders and is responsible for most cases of liver failure and liver cancer in this country,” Prof Gane says.

“The decision by PHARMAC to fund lamivudine in 2000 represented the first advance in the management of this condition. Since then, more than 1500 New Zealanders have been treated with lamivudine, many of whom already had very advanced liver disease.

“Over this period, the proportion of liver transplants performed for chronic hepatitis B has fallen from more than 50% to less than 5%. Unfortunately, some of these patients have subsequently developed lamivudine resistance, resulting in hepatitis flares, liver failure and death. Adefovir will now provide an effective means to rescue these patients and further reduce the need for liver transplantation.

“Therefore, this decision by PHARMAC to expand criteria for lamivudine treatment and to provide adefovir rescue therapy for lamivudine resistance will ensure that New Zealanders with chronic hepatitis B infection will have access to the best antiviral therapies currently available.”

Under the changes, subsidised lamivudine treatment can continue beyond three years and extend to other patient groups, such as breast feeding and pregnant women and patients with hepatocellular carcinoma.

Lamivudine will also be subsidised when used in combination with adefovir, either in patients with cirrhosis or following failure of adefovir treatment on its own. Adefovir is subsidised for patients who have become resistant to lamivudine.

[ENDS]

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

ALSO:

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

Negotiations Begin: Equal Conditions For Men & Women In Professional Football

The trade union representing New Zealand's professional footballers has initiated bargaining for an agreement securing equal terms and conditions for men and women. If negotiated, it will be the first agreement of its kind in the world. More>>

ALSO:


New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>

ALSO:


Howard Davis Review: Conflict & Resistance - Ria Hall's Rules of Engagement

From the aftermath of war through colonisation to her own personal convictions, Hall's new CD addresses current issues and social problems on multiple levels, confirming her position as a polemical and preeminent voice on the indigenous NZ music scene. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland